Our data therefore support further investigation of the therapeutic utility of PIs combined with BH3-mimetics and chemotherapy in human NSCLC tumors expressing Onc-p53, as novel therapeutic strategies are needed for the many patients with NSCLC who do not benefit from current targeted or immunotherapies. This evidence concerns the gene TP53 and non-small cell lung carcinoma.